Proceeds from the second tranche will be used to advance ATTO-1310 through early clinical trials, move the Company’s second program, ATTO-002, a bispecific IL31 x IL13 ligand trap, toward IND ...

This includes ATTO-3712, a first-in-class anti-IL13 x IL31, half-life extended bispecific that will be developed for the treatment of atopic dermatitis and other inflammatory conditions; ATTO-004 ...